KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Common Equity: 2009-2024

Historic Common Equity for Quest Diagnostics (DGX) over the last 16 years, with Dec 2024 value amounting to $6.8 billion.

  • Quest Diagnostics' Common Equity rose 6.64% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year increase of 6.64%. This contributed to the annual value of $6.8 billion for FY2024, which is 7.43% up from last year.
  • Per Quest Diagnostics' latest filing, its Common Equity stood at $6.8 billion for FY2024, which was up 7.43% from $6.3 billion recorded in FY2023.
  • Quest Diagnostics' Common Equity's 5-year high stood at $6.8 billion during FY2024, with a 5-year trough of $5.9 billion in FY2022.
  • In the last 3 years, Quest Diagnostics' Common Equity had a median value of $6.3 billion in 2023 and averaged $6.4 billion.
  • As far as peak fluctuations go, Quest Diagnostics' Common Equity increased by 19.73% in 2020, and later declined by 8.53% in 2022.
  • Quest Diagnostics' Common Equity (Yearly) stood at $6.8 billion in 2020, then fell by 4.79% to $6.5 billion in 2021, then decreased by 8.53% to $5.9 billion in 2022, then increased by 6.95% to $6.3 billion in 2023, then increased by 7.43% to $6.8 billion in 2024.